

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**VOLUNTARY ANNOUNCEMENT
FULL-DEPARTMENT APPLICATION OF TOUMAI
LAPAROSCOPIC SURGERY ROBOT FOR REMOTE
SURGERY OBTAINED THE EU CE MARK**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group’s self-developed Full-department Application of Toumai Laparoscopic Surgery Robot for Remote Surgery (“**Toumai Remote**”), which is applicable to remote laparoscopic surgeries in urology, general surgery, thoracic surgery and gynecology, has officially obtained the EU CE Mark, making it the first remote surgical robot to obtain the EU CE mark.

IMPACT ON THE COMPANY

As the world’s first and only commercialised remote surgical system that can support applications across all clinical departments and all surgical indications, Toumai Remote’s commercial application has already obtained regulatory approvals in nearly 20 countries and regions worldwide. The grant of CE mark to Toumai Remote in the EU with new market access to over 30 major European countries not only represents another milestone breakthrough for the Group in leading technological and application development in the global surgical robotics field, it also marks the first time the EU has, at a regulatory level, formally recognised “remote surgery” as a safe, effective and commercially viable medical model. This approval further demonstrates the core competitiveness of Chinese laparoscopic surgical robot manufacturers in reaching the forefront of high-end medical equipment globally. Building on this achievement, the Company will continue to deliver innovative solutions to reshape the balanced allocation of global medical resources across multiple dimensions, including the formulation of industrial standards, technological paradigms, commercial ecosystems and industrial landscape planning for the surgical robot industry.

ABOUT TOUMAI REMOTE

Toumai Remote is a remote surgery system application for the Company's core product, Toumai Laparoscopic Surgical Robot. It is a world-first-in-class technology that is compatible with multiple communication networks, and it has technical advantages in low-latency master-slave control, high-bandwidth network communication and high-stability system architecture design. Leveraging its comprehensive self-developed technology system, Toumai Remote breaks the geographical and equipment constraints of traditional surgery and pioneers a new model of third-generation remote surgery. From dedicated private line networks and 5G networks to ordinary broadband, as well as the space-air-ground integrated satellite communication network, Toumai has been continuously accelerating the evolution of remote surgery toward low cost, wide coverage, robust connectivity and high accessibility, greatly improving the precision and practical implementability of remote surgical operations.

To date, Toumai has facilitated over half of all laparoscopic surgical robot remote surgeries performed worldwide, covering nearly 30 countries and regions across Asia, Europe, North America, South America and Africa, with all surgeries successfully completed. Since the beginning of 2026, Toumai has successively assisted experts from China, the United Kingdom, Brazil, Thailand, India and other countries in performing inter-provincial, cross-border and intercontinental remote robotic surgeries, covering complex and high-difficulty procedures across multiple clinical specialties, including cardiac surgery, urology, general surgery, thoracic surgery and gynaecology. The longest surgical distance reached 18,900 kilometres, representing a truly "half-the-globe" remote surgical collaboration.

The above information is provided by the Company on a voluntary basis to provide the shareholders of the Company (the "**Shareholders**") and potential investors with the update on the latest business development of the Group.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 22 June 2026

As at the date of this announcement, the executive Directors are Dr. Chao He and Mr. Yu Liu, the non-executive Directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive Directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.